


07-03-02

RECEIVED

JUL 14 2003

TECH CENTER 1600/2900

Express Mail No.: EL 477 037 802 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Sakata et al.

Application No.: 10/071,390

Filed: February 7, 2002

For: ISOTHIAZOLOANTHRONES,
ISOXAZOLOANTHRONES,
ISOINDOLANTHRONES AND
DERIVATIVES THEREOF AS JNK
INHIBITORS AND
COMPOSITIONS AND METHODS
RELATED THERETO

Confirmation No.: 8859

Group Art Unit: 1755

Examiner: To Be Assigned

Attorney Docket No.: 10624-053-999

RECEIVED
JUL 11 2003
GROUP 1700

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with Applicants' duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97, Attorneys for Applicants hereby invite the Examiner's attention to References **AA-CH** cited in a revised PTO Form-1449 filed herewith. A copy of References **AA-CH** is also submitted herewith.

Identification of the cited references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references therein as "Prior Art." As an alternative, Applicants submit herewith the "revised PTO Form-1449," described above, entitled "List of References Cited" instead of "List of Prior Art Cited." Applicants respectfully request that References **AA-CH** be considered by the Examiner and made of record in the above-identified application file.

RECEIVED
JUL -8 2002
TECHNOLOGY CENTER 1700

Pursuant to 37 C.F.R. §1.97(b), this Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits, therefore, it is believed that no fee is required.

In the event that the Patent Office believes that a fee is due, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Date July 2, 2002

Respectfully submitted,
Anthony M. Insogna, N.Y. No. 35,203
By: Matthew E. Lape, N.Y. No. 36,343
35,203

Anthony M. Insogna

(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10624-053-999

APPLICATION NO.

10/071,390

APPLICANT

Sakata and Raymond

FILING DATE

February 7, 2002

RECEIVED
JUL 11 2003
GROUP 1700

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,162,613	12/19/00	Su et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AB	FR 2 336 708 A	07/22/77	France				
	AC	FR 2 167 626 A	08/24/73	France				
	AD	FR 2 024 807 A	09/04/70	France				
	AE	FR 2 401 915 A	03/30/79	France				
	AF	WO 01/12621 A1	02/22/01	PCT				
	AG	WO 00/75118	12/14/00	PCT				
	AH	WO 00/64872	11/2/00	PCT				
	AI	WO 99/57253	11/11/99	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)


	AJ	Ames et al., 1987, Free Radical Biol. Med., 3(2):85-96, "An integrated concept of amebicidal action: electron transfer and oxy radicals" (CHEMABS ONLINE)
	AK	Aspenstrom et al., 1996, "Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome", <i>Curr. Biol.</i> 6:70-77
	AL	Chen et al., 1996, "Activation and inhibition of the AP-1 complex in human breast cancer cells", <i>Mol. Carcinogenesis</i> 15:215-226
	AM	Deacon et al., 1999, "MEK kinase 3 directly activates MKK6 and MKK7, specific activators of the p38 and c-Jun NH2-terminal kinases", <i>J. Biol. Chem.</i> 274:16604-16610
	AN	Dong et al., 1998, "Defective T cell differentiation in the absence of Jnk1", <i>Science</i> 282:2092-2095
	AO	Faris et al., 1996, "Regulation of interleukin-2 transcription by inducible stable expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinase in Jurkat T cells", <i>J. Biol. Chem.</i> 271:27366-27373
	AP	Galushko et al., 1977, Khim. Geterotsikl. Soedin., 7:956-61, "Derivatives of pyrazoloanthrone. I. Reactivity of 2-aminopyrazoloanthrone" (CHEMABS ONLINE)
	AQ	Gum et al., 1997, "Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades", <i>Oncogene</i> 14:1481-1493
	AR	Gvon et al., 1994, Dokl. Akad. Nauk, 334(4):465-8, "Amino-amino tautomerism and intramolecular cyclization of 4,9-diamino-1,10-anthraquinone-1-tosylimines" (CHEMABS ONLINE)
	AS	Han et al., 1999, "Jun N-terminal kinase in rheumatoid arthritis", <i>J. Pharm. Exp. Therap.</i> 291:1-7
	AT	Hartley et al., 1988, Mol. Pharmacol., 33(3):265-71, "Characteristics of the interaction of anthrapyrazole anticancer agents with deoxyribonucleic acids: structural requirements for DNA binding, intercalation, and photosensitization" (CHEMABS ONLINE)
	AU	Herdegen et al., 1998, "Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury", <i>J. Neurosci.</i> 18:5124-5135

AV	Hibi et al., 1993, "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain", <i>M. Genes Dev.</i> 7:2135-2148
AW	Ishizuka et al., 1997, "Mast cell tumor necrosis factor alpha production is regulated by MEK kinases", <i>Proc. Nat. Acad. Sci. USA</i> 94:6358-6363
AX	Ivanova et al., 1997, Poverkhnost, 4-5:193-201, "IPS investigation of electronic structure of pyrazolanthrone and its derivatives" (CHEMABS ONLINE)
AY	Judson, 1992, Semin. Oncol. 19(6):687-94, "The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer" (CHEMABS ONLINE)
AZ	Kiyooka et al., 1990, "Photochemical Intramolecular Cyclization Reactions of Acylgermanes", <i>Jr. J. Org. Chem.</i> 55, 5562-4
BA	Karin et al., 1997, "AP-1 function and regulation", <i>Curr Opin Cell Biol</i> 9:240-246.
BB	Lange-Carter et al., 1993, "A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf.", <i>Science</i> 260:315-319
BC	Li et al., 1996, "Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4 ⁺ T cells", <i>Science</i> 271: 1272-1276
BD	Li et al., 1996, "The Ras-JNK pathway is involved in shear-induced gene expression", <i>Mol. Cell. Biol.</i> 16:5947-5954
BE	Lin et al., 1995, "Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2", <i>Science</i> 268:286-289
BF	Maj et al., 1992, "PNU 151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat", <i>Eur. J. Pharm.</i> 359:27-32, 1992.
BG	Manning et al., "Transcription inhibitors in inflammation", <i>Exp. Opin. Invest. Drugs</i> 6: 555-567
BH	Maroney et al., 1998, "Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway", <i>J. Neurosci.</i> 18:104-111
BI	Mielke et al., 2000, "JNK and p38 stresskinases--degenerative effectors of signal-transduction-cascades in the nervous system", <i>Prog. Neurobiol.</i> 61:45-60
BJ	Milne et al., 1995, "p53 is phosphorylated <i>in vitro</i> and <i>in vivo</i> by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1", <i>J. Biol. Chem.</i> 270:5511-5518
BK	Mohit et al., 1995, "p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system", <i>C.A. Neuron</i> 14:67-75
BL	Nishina et al., 1997, "Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes", <i>J. Exp. Med.</i> 186:941-953
BM	Okamoto et al., 1997, "Selective activation of the JNK/AP-1 pathway in Fas-mediated apoptosis of rheumatoid arthritis synoviocytes", <i>Arth & Rheum</i> 40: 919-926
BN	Pombo et al., 1994, "The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion", <i>J. Biol. Chem.</i> 269:26546-26551
BO	Raitano et al., 1995, "The <i>Bcr-Abl</i> leukemia oncogene activates Jun kinase and requires Jun for transformation", <i>Proc. Nat. Acad. Sci. USA</i> 92:11746-11750
BP	Richards et al, <i>Am. J. Physiol.</i> 271:2, Pt 1, L267-76, 1996.
BQ	Sabapathy et al., 1999, "JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development", <i>Curr Biol</i> 9:116-125
BR	Saporito et al., 1998, "Preservation of cholinergic activity and prevention of neuron death by CEP-1347/KT-7515 following excitotoxic injury of the nucleus basalis magnocellularis", <i>Neuroscience</i> 86:461-472
BS	Saporito et al., 1999, "CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons <i>In vivo</i> ", <i>J Pharmacol Exp Ther.</i> 288(2):421-7
BT	Showalter et al., 1984, <i>J. Med. Chem.</i> , 27(3):253-5, "5-(Aminoalkyl)amino-1-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation"
BU	Showalter et al., 1987, <i>J. Med. Chem.</i> , 30(1):121-31, "Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias" (CHEMABS ONLINE)

RECEIVED

JUL 11 2003

GROUP 1700



BV	Singh, et al., 1978, Indian J. Chem. Sect. B, 16B(2):100-2, "Reactions of 2,2'-ethylenebis(anthrapyrazolone)" (CHEMABS ONLINE)
BW	Sokolyuk et al., 1992, 28(10):2193-200, "Synthesis and photochemical properties of peri-phenoxy derivatives of 6H-anthra'1,9-cd!-6-pyrazolone (pyrazole anthrone)" (CHEMABS ONLINE)
BX	Su et al., 1994, "JNK is involved in signal integration during costimulation of T lymphocytes", <i>Cell</i> 77:727-736
BY	Swantek et al., 1997, "Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK", <i>Mol. Cell. Biol.</i> 17:6274-6282
BZ	Szabo et al., "Altered cJUN expression: an early event in human lung carcinogenesis" <i>Cancer Res.</i> 56:305-315, 1996
CA	Teramoto et al., 1996, "Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family", <i>J. Biol. Chem.</i> 271:27225-27228
CB	Tournier et al., 1997, "Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase", <i>Proc. Nat. Acad. Sci. USA</i> 94:7337-7342
CC	Whitmarsh et al., 1996, "Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways", <i>J. Mol. Med.</i> 74:589-607
CD	Winter et al, <i>Arthritis and Rheumatism</i> 9(3):394-404, 1966; Weichman et al, <i>Pharmacological Methods in the Control of Inflammation</i> , Chang and Lewis Eds., Alan R. Liss, Inc., Publ., New York, 1989.
CE	Yan et al., 1994, "Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1", <i>Nature</i> 372:798-800
CF	Yang et al., 1998, "Differentiation of CD4 ⁺ T cells to Th1 cells requires MAP kinase JNK2", <i>Immunity</i> , 9:575-585
CG	Yang et al., 1997, "Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene", <i>Nature</i> 389:865-870
CH	Yin et al., "Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney", <i>J. Biol. Chem.</i> 272:19943-19950

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TECH CENTER 1600/2900

JUL 14 2003

RECEIVED

 RECEIVED
 JUL -8 2002
 TECHNOLOGY CENTER 1700